Advocacy

Home / Advocacy

Advocacy

 

The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology.  AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals. 

In 2015, AMP plans to continue addressing many regulatory and reimbursement forces adversely affecting molecular diagnostic testing.In January, AMP released a white paper titled A Molecular Diagnostic Perfect Storm: The Convergence of Regulatory & Reimbursement Forces that Threaten Patient Access to Innovations in Genomic Medicine detailing these challenges and utilizes it to support advocacy initiatives.

Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas. We invite you to explore AMP's Position Statements and Letters. For more information, please contact policy@amp.org.

View all AMP Position Statements and Letters

Laboratory Developed Testing Procedures (LDPs)

 

JUST RELEASED:

AMP's Analysis of FDA's Report Titled "The Public Health Evidence for FDA Oversight of LDTs: 20 Case Studies"

 

TOP ISSUE:

CLIA Modernization Proposal

 

CLICK HERE TO DOWNLOAD!

 

CLICK HERE TO LEARN MORE!

 

 

AMP's Written Testimony to Hearing on "Examining the Regulation of Diagnostic Tests and Laboratory Operations"

 

Laboratory Testing and Patient Care - View Video

 

AMP's Principles for Oversight of LDPs

 

Comments to House E&C Committee on Regulation of In Vitro Clinical Tests Draft Legislation

 

Written comments to FDA on Proposed Oversight of LDPs

 

Signs from the 2014 Annual Meeting:  Are you ready to be a "manufacturer"?

 

AMP Position Statement: Revisiting Oversight and Regulation of Molecular-Based Laboratory-Developed Tests

 

FDA's website devoted to all information relevant to the draft framework: www.FDA.gov/LDTs

 

Coverage and Reimbursement

 

TOP ISSUE:

Genomic Sequencing Procedure Cost and Value Models-Free Download Available!

 

 

Comments to CMS on the Medicare Clinical Diagnostic Laboratory Tests Payment System Proposed Rule

 

Comments to CMS on CLFS for CY2016

 

Comments to CMS on Preliminary Gapfill Determinations

 

Comments to CMS on Section 1834A of the Protecting Access to Medicare Act of 2014 (PAMA)